Abstract 152P
Background
Neoadjuvant chemoradiotherapy (nCRT) is the standard initial treatment for locally advanced rectal cancer (LARC) to reduce tumor size before surgery. Although some patients achieve complete pathological response and become eligible for organ-preserving strategies, predicting nCRT response remains challenging. The intratumoral genetic heterogeneity (ITGH) has emerged as a potential biomarker in LARC patients. Tumor-infiltrating lymphocytes (TILs) enriched with cytotoxic CD8+ T-cells indicate better prognosis and treatment response. An immunohistochemistry-based score, estimating CD3+ and CD8+ enrichment in LARC TILs, is proposed as a predictive test. Elements from anti-tumoral immune response could serve as potential predictive biomarkers.
Methods
We analyzed 80 primary LARC tumors (18 responders, nCRT-R, versus nonresponders 62, nCRT-NR) through WXS and TCRseq. We evaluated nCRT response, tumor mutation burden (TMB), neoantigen load (NAL), HLA polymorphism, somatic mutation, TCR diversity/clonality, ITGH levels, and DNA mismatch repair deficiency.
Results
We identified six significantly mutated genes (KRAS, APC, TP53, FBXW7, ARID1A, SLITRK6) (p<0.05; FDR<=0.1). Somatic mutations in driver genes, 23 dMMR genes, and COSMIC somatic signatures S6, S15, S20, or S26 did not show any association with nCRT response (p>0.5; Fisher Test). We measured ITGH through MATH score, but no significant difference between nCRT-R and NR (p=0.8; Wilcoxon test) was observed. TMB and NAL were significantly higher in nCRT-NR (p<0.05). HLA somatic mutation did not have a significant impact on antigen presentation and treatment response (8 mutations in 8 patients; Pearson Chi-squared, p=0.76). HLA polymorphism was not relevant (Pearson Chi-squared, p=0.64). Finally, nCRT response was not associated with TCR Shannon diversity or clonality (Wilcoxon test, p=0.25 and p=0.48, respectively); however, we could not quantify CD8+ T-cells.
Conclusions
Gene driver signature, ITGH, or dMMR mutations/signatures were not predictive biomarkers of nCRT response; however, preliminary findings suggest a subset of highly immunogenic nCRT-NR LARCs patients could benefit from immunotherapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
R. Perez.
Funding
FAPESP: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Hypomethylated immune gene promoters as potential biomarkers in oral and oropharyngeal cancer
Presenter: Petra Anić
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Implementation of technical improvements in cfMeDIP-Seq library preparation
Presenter: Martina Dameri
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Clinical application of next-generation sequencing in metastatic colorectal cancer (mCRC): Experience from a comprehensive cancer centre
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
108P - Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study
Presenter: Rachel Dodds
Session: Cocktail & Poster Display session
Resources:
Abstract
109P - A multiomic, single-cell measurable residual disease (scMRD) assay for phasing DNA mutations and surface immunophenotypes
Presenter: Simone Formisano
Session: Cocktail & Poster Display session
Resources:
Abstract
110P - Multicellular three-dimensional tumor spheroid of nasopharyngeal carcinoma
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
111P - Development of digital PCR for accurate measurement of HER2 amplification in 184 gastric cancer patients
Presenter: So Young Kang
Session: Cocktail & Poster Display session
Resources:
Abstract
112P - A novel methylation-sensitive assay for early detection of hepatocellular carcinoma to improve surveillance
Presenter: Jeong Sil Ha
Session: Cocktail & Poster Display session
Resources:
Abstract